Incyte Corporation

This study tested a cream called ruxolitinib for people with vitiligo affecting their genital area. Forty-nine participants applied the cream twice daily for up to 48 weeks to see if it could help restore skin color and reduce the noticeability of the condition. Researchers measu…

This Phase 3 study tested whether an oral medication called povorcitinib can safely reduce symptoms of moderate to severe hidradenitis suppurativa (HS), a chronic inflammatory skin disease. The trial involved 608 participants who had not responded well to previous treatments. For…

This study tested three different treatment approaches for people with advanced head and neck cancer that had returned or spread. Researchers compared two immunotherapy-based treatments (pembrolizumab with or without epacadostat) against a standard chemotherapy combination called…

This study tested an oral drug called pemigatinib in people with a rare and aggressive type of blood cancer caused by a specific genetic change (FGFR1 rearrangement). The goal was to see if the drug could effectively control the disease and was safe to use. It involved 47 partici…

This study tested an oral medication called povorcitinib for adults with chronic spontaneous urticaria (long-lasting, unpredictable hives) that standard antihistamines could not control. The goal was to see if different doses of the drug could safely reduce hive and itch severity…

This study tested whether adding an immunotherapy drug called retifanlimab (INCMGA00012) to standard chemotherapy could better control advanced anal cancer that cannot be surgically removed. It involved 308 adults with cancer that had returned locally or spread, who had not recei…

This early-stage study tested a new drug called INCA32459 in 46 people with advanced cancers that had stopped responding to standard treatments. The main goals were to find a safe dose and see how the body processes the drug. Researchers also looked for early signs that the drug …

This study tested a cream called ruxolitinib for adults with moderate atopic dermatitis (eczema) who did not get enough relief from standard topical treatments like steroid creams. The goal was to see if the cream could safely reduce the severity of eczema and the intense itching…

This study tested whether adding a new drug called itacitinib to an existing lung cancer medication (osimertinib) is safe and effective. It involved 59 adults with advanced non-small cell lung cancer that had specific genetic changes (EGFR and T790M mutations) and had stopped res…

This Phase 3 study tested an oral medication called povorcitinib for people with moderate to severe hidradenitis suppurativa (HS), a chronic, painful skin condition. The 619 participants took either the drug or a placebo for 12 weeks, with many continuing for an additional 42 wee…

This study tested whether adding the drug ruxolitinib to standard chemotherapy could help children with a particularly aggressive form of acute lymphoblastic leukemia (ALL). It involved 171 children and young adults (ages 1-21) who had specific genetic markers that make their can…

This study tested whether adding the drug itacitinib to standard steroid treatment works better for controlling acute graft-versus-host disease (GVHD) in people who recently had a stem cell transplant. It involved 439 participants who developed moderate to severe GVHD. The goal w…

This study tested a combination of three immunotherapy drugs for people with advanced melanoma, a serious skin cancer. The main goals were to find safe doses and see if the treatment could shrink tumors, especially in patients whose cancer had stopped responding to standard immun…

This study tested a drug called itacitinib for people with a serious bone marrow cancer called myelofibrosis who had already tried other standard treatments. The main goals were to find a safe dose and see if the drug could reduce spleen size and improve symptoms. Only four peopl…

This study tested whether a cream containing ruxolitinib could safely reduce severe itch and improve skin lesions in people with prurigo nodularis, a chronic skin condition. Over 200 participants applied either the active cream or a placebo cream for 12 weeks, followed by an exte…

This study tested a cream called ruxolitinib to see if it safely reduces severe itch and improves skin lesions in people with prurigo nodularis, a chronic skin condition. 190 participants with intense, long-lasting itch applied the cream or a placebo for 12 weeks, followed by an …

This study aimed to understand how a new drug called INCB123667 is processed by the body. Nine healthy male volunteers took a single oral dose containing a tiny, safe amount of radioactive tracer. Researchers then tracked exactly how much of the drug was absorbed, how long it sta…

This early-stage study aimed to understand how a new drug candidate, INCB099280, is processed by the body. Five healthy male volunteers took a single, specially labeled oral dose. Researchers then carefully measured how much of the drug was absorbed, how long it stayed in the bod…

This early-stage study aimed to understand how three common types of medications—an antifungal, an antibiotic, and heartburn drugs—affect the body's processing of an experimental drug called INCB161734. It involved 63 healthy adult volunteers who took the experimental drug alone …

This early-stage study tested a new oral drug called INCB160058 in healthy adults to check its safety and see how the body processes it. Researchers gave single doses to 137 healthy volunteers to monitor for side effects and measure drug levels in the blood. The study also examin…

This study tested a new method using tiny needles to collect fluid from just under the skin. It involved 20 people, both healthy volunteers and those with atopic dermatitis (eczema). The goal was to see if this method works well and is comfortable, to help researchers better unde…